Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.53 |
| ▸ | IKBKB | O14920 | 8/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | CHUK | O15111 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31188482 | 1.00 | ADRB1 (0.60) | ADRB1HPGDSCN9AIKBKBOPRM1 | |
| SCHEMBL5088410 | 1.00 | ADRB1 (0.60) | ADRB1HPGDSCN9AIKBKBOPRM1 | |
| SCHEMBL3760743 | 0.95 | ADRB1 (0.59) | ADRB1HPGDSCN9AIKBKBOPRM1 | |
| SCHEMBL6221703 | 0.95 | ADRB1 (0.59) | ADRB1HPGDSCN9AIKBKBOPRM1 | |
| SCHEMBL3036514 | 0.85 | SCN9A (0.54) | SCN9AIKBKBHDAC4HDAC6CHUK | |
| SCHEMBL3043463 | 0.85 | SCN9A (0.51) | ADRB1SCN9AIKBKBHDAC4HDAC6 | |
| SCHEMBL3289066 | 0.85 | ACHE (0.52) | ADRB1 | |
| SCHEMBL279926 | 0.85 | SCN9A (0.54) | HPGDSCN9AIKBKBOPRM1HDAC4 | |
| SCHEMBL13100535 | 0.84 | THRB (0.54) | IKBKBHDAC6DPP4ROCK2ROCK1 | |
| SCHEMBL279575 | 0.84 | HPGD (0.59) | HPGDSCN9AOPRM1HDAC6PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112533904-B | Melanocortin subtype-2 receptor (MC 2R) antagonists and uses thereof | 克林提克斯医药股份有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-109476633-A | The inhibitor of tryptophan 2,3- dioxygenase | 荷兰转化研究中心有限责任公司 | 2019-03-15 | — | — | CN | disclosed |
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| EP-1613304-B1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS CH (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2005120494-A1 | 1-`(3R)-AMINO-4-(2-FLUORO-PHENYL)-BUTYL !-PYRROLIDINE-(2R)-CARBOXILIC ACID-BENZYL AMINE DERIVATIVES AND RELATED COMPOUNDS AS DIPEPTIDYL-PEPTIDASE IV (DPP-IV) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005056003-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027035-A1 | Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | ADRB1 525/4885HPGD 2812/4885SCN9A 1489/4885 |
| US-20080176838-A1 | Dpp-IV Inhibitors | DPP4, DPP9, DPP7 | ADRB1 723/4885HPGD 3617/4885SCN9A 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.